- Home
- / Waverley Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Waverley Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$810 K
2024-10-29
Revenue
$475 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 223.0K | 1.2M | 1.4M | 1.8M | 1.2M | 412.0K | 475.0K |
| Cost of goods sold | 191.0K | 1.1M | 1.2M | 1.5M | 963.0K | 332.0K | 238.0K |
| Gross profit | 38.0K | 49.0K | 194.0K | 265.0K | 284.0K | 80.0K | 237.0K |
| Gross profit margin, % | 4.2% | 14.1% | 15.1% | 22.8% | 19.4% | 49.9% | |
| Operating expense total | 1.5M | 1.5M | 891.0K | 1.0M | 1.2M | 1.4M | 1.1M |
| Depreciation and amortization | 942.0K | 23.0K | |||||
| EBITDA | (1.5M) | (1.4M) | (697.0K) | (745.0K) | (936.0K) | (1.3M) | (839.0K) |
| EBITDA margin, % | -122.1% | -50.7% | -42.5% | -75.1% | -311.2% | -176.6% | |
| EBIT | (1.5M) | (1.3M) | (697.0K) | (745.0K) | (638.0K) | (2.1M) | (744.0K) |
| EBIT margin, % | -108.9% | -50.7% | -42.5% | -51.2% | -520.9% | -156.6% | |
| Interest income | 65.0K | 46.0K | 5.0K | 1.0K | |||
| Interest expense | 3.0K | 17.0K | 77.0K | 163.0K | |||
| Pre tax profit | (1.4M) | (1.2M) | (705.0K) | (797.0K) | (664.0K) | (2.2M) | (947.0K) |
| Net Income | (1.4M) | (1.2M) | (705.0K) | (797.0K) | (664.0K) | (2.2M) | (947.0K) |